US FDA approves higher dose of Novartis Exelon Patch
This article was originally published in Scrip
Executive Summary
The US FDA has approved a higher, 13.3 mg dose of Novartis' Exelon Patch (rivastigmine transdermal system) for treating patients with mild to moderate Alzheimer's disease.